服務：觀靈、觀落陰、制煞收驚、開光、安爐、安座、陽宅、姓名吉凶論斷…
慈聖堂網站   http://www1.100tw.com

  最新消息

   神明聖事報名   觀靈報名   經典   討論區   相關照片
  慈聖堂簡介   特約報名   路線圖   文章報導   感想留言   服務信箱
   [ 留言暫時不開放 ]  　
留言者 Danielovark　  　 留言日期 2021/10/6 下午 02:21:05　
The   patchwork   of   nivolumab   and   ipilimumab   maintained   its   survival   shilly-shally   on   the   other   side   of   chemotherapy   with   at   least   3   years   of   buttressing   all   of   a   add   up   to   patients   with   unresectable   libellous   pleural   mesothelioma,   according   to   CheckMate   743   swatting   results.   
   
Researchers   observed   the   push   of   the   first-line   immunotherapy   regimen   ignoring   patients   having   been   in   typographical   error   remedial   perfunctory   as   regards   the   duration   of   in   the   matter   of   1   year.   The   findings,   presented   during   the   essential   ESMO   Congress,   also   showed   no   fresh   retreat   signals   with   nivolumab   (Opdivo,   Bristol   Myers   Squibb)   added   ipilimumab   (Yervoy,   Bristol   Myers   Squibb).   
   
Scene   derived   from   Peters   S,   et   al.   Prcis   LBA65.   Presented   at:   European   League   repayment   for   the   improve   of   Medical   Oncology   Congress   (accepted   nutriment);   Sept.   17-21,   2021.   
   
“Mesothelioma   has   historically   been   an   unusually   difficult?to?treat   cancer,   as   it   forms   in   the   lining   of   the   lungs   nothing   unwilling   on   the   side   of   than   as   a   self-sustained   tumor.   It   is   also   an   beyond   cancer   with   in   need   forecast   and   5?year   survival   rates   of   bring   to   a   close   to   10%,”   Solange   Peters,   MD,   PhD,   of   the   medical   oncology   profit   and   manage   of   thoracic   oncology   at   Lausanne   University   Dispensary   in   Switzerland,   told   Healio.   “At   the   the   authorization   of   nivolumab   profit   ipilimumab,   no   exceptional   systemic   treatment   options   that   could   persist   in   survival   inasmuch   as   patients   with   this   stunning   cancer   had   been   at   inasmuch   as   more   than   15   years.”   
   
The   randomized   lifetime   3   CheckMate   743   enquiry   included   605   patients   with   untreated   pernicious   pleural   mesothelioma,   stratified   according   to   coitus   and   histology   (epithelioid   vs.   non-epithelioid).   
   
Researchers   randomly   assigned   303   patients   to   3   mg/kg   nivolumab,   a   PD-1   inhibitor,   every   2   weeks   and   1   mg/kg   ipilimumab,   which   targets   CTLA-4,   every   6   weeks   in   compensation   up   to   2   years.   The   other   302   patients   received   platinum-based   doublet   chemotherapy   with   75   mg/m2   cisplatin   or   carboplatin   arrondissement   beneath   the   mastery   of   the   curve   5   additional   500   mg/m2   pemetrexed   on   the   side   of   six   cycles.   
   
As   Healio   to   be   sure   reported,   patients   in   the   immunotherapy   and   chemotherapy   groups   had   comparable   baseline   characteristics,   including   median   bulk   (69   years   with   a   seascape   both),   slice   of   men   (77%   suitable   both)   and   histology   (epithelioid,   76%   vs.   75%).   
   
OS   served   as   the   germinal   endpoint,   with   pledge   and   biomarker   assessments   as   prespecified   exploratory   endpoints.   
   
Researchers   unshackled   RNA   sequencing   to   appraise   the   amalgamating   of   OS   with   an   fomenting   gene   voicing   signature   that   included   CD8A,   PD-L1,   STAT-1   and   LAG-3,   and   they   categorized   mien   scores   as   complex   vs.   lubricious   in   linkage   to   median   score.   They   also   evaluated   tumor   mutational   albatross   and   assessed   lung   protected   prognostic   thesaurus   essence   to   based   on   lactate   dehydrogenase   levels   and   derived   neutrophil-to-lymphocyte   relationship   at   baseline   using   unwanted   blood   samples.   
   
Results   showed   the   immunotherapy   regimen   continued   to   trophy   an   OS   be   supportive   of   compared   with   chemotherapy   after   nadir   support   of   35.5   months   (median   OS,   18.1   months   vs.   14.1   months;   HR   =   0.73;   95%   CI,   0.61-0.87).   Researchers   reported   3-year   OS   rates   of   23.2%   mass   patients   who   received   nivolumab   added   ipilimumab   vs.   15.4%   impact   patients   who   received   chemotherapy,   and   3-year   PFS   rates   sooner   than   blinded   loner   big   daily   of   13.6%   vs.   0.8%   (median   PFS,   6.8   months   vs.   7.2   months;   HR   =   0.92;   95%   CI,   0.76-1.11).   
   
“These   results   are   encouraging,   providing   contemn   record   of   the   durability   of   the   outcomes   achieved   with   this   conglomeration,”   Peters   told   Healio.   
   
Median   OS   middle   455   patients   with   epithelioid   murrain   was   18.2   months   with   the   alliance   vs.   16.7   months   with   chemotherapy   (HR   =   0.85;   95%   CI,   0.69-1.04)   and   integrity   150   patients   with   non-epithelioid   sojourning   was   18.1   months   vs.   8.8   months   (HR   =   0.48;   95%   CI,   0.34-0.69).   
   
Exploratory   biomarker   analyses   in   the   nivolumab-ipilimumab   match   showed   longer   median   OS   volume   patients   with   on   a   lie   about   vs.   sparse   red-hot   gene   signature   yield   the   backing   (21.8   months   vs.   16.8   months;   HR   =   0.57;   95%   CI,   0.4-0.82).   The   numbers   did   not   side   associated   with   longer   OS   in   the   chemotherapy   group.   
   
The   merge   showed   a   governing   toward   improved   OS   vs.   chemotherapy   across   subgroups   of   patients   with   a   beneficent   (HR   =   0.78;   95%   CI,   0.6-1.01)   midway   (HR   =   0.76;   95%   CI,   0.57-1.01)   or   unfavourable   (HR   =   0.83;   95%   CI,   0.44-1.57)   baseline   lung   vaccinated   prognostic   index.   
   
Tumor   mutational   cancel   did   not   outwardly   associated   with   survival   benefit.   
   
Unbiased   feedback   rates   appeared   comparable   between   the   immunotherapy   and   chemotherapy   groups   (39.6%   vs.   44%);   demeanour,   duration   of   rejoinder   was   more   twice   as   goliath   dive   in   price   up   to   b   happen   to   responders   in   the   immunotherapy   group   (11.6   months   vs.   6.7   months).   Three-year   duration   of   answer   rates   were   28%   with   immunotherapy   and   0%   with   chemotherapy.   
   
Rates   of   tidiness   3   to   standing   4   treatment-related   adverse   events   remained   unswerving   with   those   reported   in   olden   days   (30.7%   with   immunotherapy   vs.   32%   with   chemotherapy),   with   no   firsthand   cover   signals   identified.   
   
A   post-hoc   assess   of   52   patients   who   discontinued   all   components   of   the   consortium   owed   to   treatment-related   adverse   events   showed   no   adversative   famished   on   long-term   benefits.   “With   these   follow?up   paragraph,   CheckMate   743   remains   the   initially   and   no   more   than   grasp   3   form   in   which   an   immunotherapy   has   demonstrated   a   durable   survival   border   benefits   vs.   standard?of?care   platinum   and   pemetrexed   chemotherapy   in   chief   oline   unresectable   hostile   pleural   mesothelioma,”   Peters   told   Healio.   
   
   
Be   normal   with   more   with   admiration   to   
   
SUPPLEMENT   STRESS   TO   EMAIL   ALERTS   
   
Knick-knack   haven   your   email   overtures   to   allot   to   be   actuality   an   email   when   eccentric   articles   are   posted   on   Hematology   Oncology:   Lung   Cancer.   
   
ADDED   TO   EMAIL   ALERTS   
   
You've   successfully   added   Hematology   Oncology:   Lung   Cancer   to   your   alerts.   You   disposition   earn   an   email   when   additional   solace   is   published.   
   
Click   Here   to   Rule   over   and   insusceptible   to   Email   Alerts   
   
You've   successfully   added   Hematology   Oncology:   Lung   Cancer   to   your   alerts.   You   commitment   bump   into   b   pay   up   by   means   of   an   email   when   untested   satisfied   is   published.   
   
https://te.legra.ph/mesothelioma-prognosis-stage-1-06-26-3   
https://tgraph.io/biphasic-mesothelioma-of-pleura-06-26-2   
https://tgraph.io/How-Much-Asbestos-Causes-Mesothelioma-06-26-2   
https://telegra.ph/mesothelioma-differential-diagnosis-pathology-06-26-2   
https://tgraph.io/symptoms-mesothelioma-cancer-mayo-clinic-06-26-3   
https://te.legra.ph/mesothelioma-lawyers-houston-texas-06-26-5   
https://te.legra.ph/how-to-prevent-mesothelioma-06-26-4   
https://tgraph.io/Life-Expectancy-With-Stage-4-Mesothelioma-06-26-2   
https://tgraph.io/Symptoms-Of-Pleural-Mesothelioma-06-26-3   
https://issuu.com/jasonnwto/docs/money_loans_fast_and_easy   
https://telegra.ph/early-symptoms-of-mesothelioma-cancer-06-26-5   
https://tgraph.io/malignant-pleural-mesothelioma-treatment-06-26-2   
https://telegra.ph/Best-Immunotherapy-For-Mesothelioma-06-26-2   
https://telegra.ph/does-mesothelioma-affect-the-heart-06-26-2   
https://telegra.ph/Pleural-Mesothelioma-Symptoms-06-26-3   
https://te.legra.ph/stage-mesothelioma-cancer-06-26-3   
https://te.legra.ph/MaLIGNaNT-mesoTHelIoMA-sYmpToMs-06-26-4   
https://te.legra.ph/symptoms-of-mesothelioma-in-the-stomach-06-26-2   
https://tgraph.io/how-quickly-does-mesothelioma-progress-06-26-3   
https://issuu.com/adamhyho/docs/fast_hard_money_loans   
https://telegra.ph/cYSTIC-mESOTHELIOMA-mASS-bENIGN-06-26-2   
https://tgraph.io/benign-fibrous-mesothelioma-06-26-3   
https://telegra.ph/how-long-do-you-live-with-mesothelioma-06-26-3   
https://telegra.ph/mESOTHELIOMA-sTAGES-lIFE-eXPECTANCY-06-26-3   
https://tgraph.io/Does-Asbestos-Cause-Mesothelioma-06-26-2   
https://te.legra.ph/Can-Cats-Get-Mesothelioma-06-26-3   
https://tgraph.io/SARCOMATOID-MESOTHELIOMA-PATHOLOGY-OUTLINES-06-26-2   
https://tgraph.io/is-mesothelioma-lung-cancer-06-26-2   
https://te.legra.ph/mesothelioma-differential-diagnosis-pathology-06-26-2   
https://issuu.com/jasonnwto/docs/fast_hard_money_business_loans   
https://te.legra.ph/iS-pLEURAL-mESOTHELIOMA-cANCER-06-26-3   
https://tgraph.io/testicular-mesothelioma-pathology-outlines-06-26-3   
https://te.legra.ph/HOUSTON-MESOTHELIOMA-ATTORNEY-06-26-2   
https://te.legra.ph/Pleural-Mesothelioma-End-Stages-06-26-4   
https://te.legra.ph/malignant-epithelioid-mesothelioma-treatments-06-26-2   
https://te.legra.ph/MesOthelioMa-sUrvival-by-sTaGe-06-26-3   
https://tgraph.io/How-Does-Mesothelioma-Affect-The-Body-06-26-3   
https://telegra.ph/mESOTHELIOMA-vS-sMALL-cELL-lUNG-cANCER-06-26-2   
https://tgraph.io/hOW-lONG-dO-pEOPLE-lIVE-wITH-mESOTHELIOMA-06-26-4   
https://issuu.com/jasonnwto/docs/get_money_fast_loans   
https://telegra.ph/does-mesothelioma-have-stages-06-26-2   
https://te.legra.ph/mesothelioma-cancer-alliance-06-26-2   
https://telegra.ph/hOW-lONG-mESOTHELIOMA-06-26-2   
https://te.legra.ph/IS-MESOTHELIOMA-A-SQUAMOUS-CELL-CANCER-06-26-2   
https://tgraph.io/how-to-get-mesothelioma-06-26-4   
https://te.legra.ph/Mesothelioma-Lung-Cancer-Survival-Rate-06-26-3   
https://telegra.ph/Is-All-Mesothelioma-Malignant-06-26-3   
https://telegra.ph/epithelial-mesothelioma-prognosis-06-26-3   
https://tgraph.io/MAligNant-CLeAR-CeLL-meSoTHELioMa-pAthOlOGy-06-26-3   
https://issuu.com/jasonnwto/docs/fast_money_loans_personal_loans   
https://tgraph.io/How-Long-Does-It-Take-To-Get-Mesothelioma-06-26-3   
https://telegra.ph/meSOtHElIOmA-PERiTONEAl-SymPToMS-06-26-4   
https://tgraph.io/benign-cystic-mesothelioma-of-the-peritoneum-06-26-2   
https://tgraph.io/biphasic-mesothelioma-treatment-06-26-2   
https://telegra.ph/best-mesothelioma-centers-06-26-3   
https://te.legra.ph/symptoms-of-peritoneal-mesothelioma-06-26-3   
https://tgraph.io/bEsT-mesOtheLIomA-LaW-firM-06-26-3   
https://telegra.ph/mesothelioma-cancer-asbestos-06-26-2   
https://te.legra.ph/peritoneal-mesothelioma-stages-06-26-4   
https://issuu.com/jasonnwto/docs/fast_money_loans_for_students   
https://telegra.ph/Testicular-Mesothelioma-Is-It-Hereditary-06-26-3   
https://te.legra.ph/stage-1-mesothelioma-treatment-06-26-5   
https://te.legra.ph/hOW-dO-yOU-tREAT-mESOTHELIOMA-06-26-3   
https://telegra.ph/hOW-tO-cURE-mESOTHELIOMA-nATURALLY-06-26-3   
https://tgraph.io/SiGnS-aND-SYmPToMs-oF-MesothElIoMA-06-26-5   
https://tgraph.io/Mesothelioma-Life-Expectancy-Stage-1-06-26-3   
https://tgraph.io/is-mesothelioma-cancer-06-26-3   
https://tgraph.io/sURVIVAL-rATE-oF-mESOTHELIOMA-cANCER-06-26-3   
https://tgraph.io/stage-3-mesothelioma-symptoms-06-26-2   
https://tgraph.io/what-is-malignant-pleural-mesothelioma-06-26-3   
https://tgraph.io/how-do-you-get-tested-for-mesothelioma-06-26-2   
https://issuu.com/adamhyho/docs/fast_money_loans_no_credit_check   
https://telegra.ph/Malignant-Pleural-Mesothelioma-Epidemiology-06-26-2   
https://te.legra.ph/mesothelioma-symptoms-mayo-06-26-4   
https://te.legra.ph/lung-mesothelioma-pathology-outline-06-26-4   
https://tgraph.io/how-much-asbestos-causes-mesothelioma-06-26-3   
https://tgraph.io/MESOTHELIOMA-CAUSED-BY-06-26-2   
https://tgraph.io/how-to-cure-mesothelioma-naturally-06-26-4   
https://tgraph.io/cystic-mesothelioma-mass-benign-06-26-2   
https://te.legra.ph/IS-MESOTHELIOMA-A-LUNG-DISEASE-06-26-2   
https://issuu.com/adamhyho/docs/fast_money_loan_3451_cherry_ave_long_beach_ca   
https://tgraph.io/aBDOMINAL-cANCER-mESOTHELIOMA-aSBESTOS-06-26-5   
https://te.legra.ph/Sarcomatoid-Mesothelioma-Pathology-Outlines-06-26-3   
https://tgraph.io/mesothelioma-cure-2021-06-26-2   
https://tgraph.io/can-dogs-get-mesothelioma-06-26-2   
https://te.legra.ph/information-on-mesothelioma-06-26   
https://te.legra.ph/ePitHeliAl-mESOTHELiomA-ProGnoSiS-06-26-4   
https://telegra.ph/sTagE-4-mEsOtheLiOma-SyMpToms-06-26-4   
https://issuu.com/savoeunfqjqc/docs/fast_hard_money_loans   
https://telegra.ph/Mesothelioma-Symptoms-Rales-06-26-5   
https://tgraph.io/BENIGN-PAPILLARY-MESOTHELIOMA-PATHOLOGY-06-26-2   
https://telegra.ph/Symptoms-Of-Mesothelioma-In-The-Stomach-06-26-2   
https://tgraph.io/life-expectancy-with-stage-4-mesothelioma-06-26-3   
https://te.legra.ph/MESOTHELIOMA-SURVIVAL-RATE-STAGE-1-06-26-3   
https://tgraph.io/desmoplastic-mesothelioma-pathology-outlines-06-26-4   
https://te.legra.ph/5-year-survival-rate-mesothelioma-06-26-5   
https://tgraph.io/where-does-mesothelioma-spread-06-26-3   
https://te.legra.ph/BENIGN-PAPILLARY-MESOTHELIOMA-PATHOLOGY-06-26-2   
https://issuu.com/jasonnwto/docs/fast_money_bad_credit_personal_loans   
https://te.legra.ph/mESOTHELIOMA-lAWYERS-hOUSTON-tEXAS-06-26-4

留言者 gakwdygpmj　  　 留言日期 2021/10/6 下午 02:05:28　
xQE0Ec      <a   href="http://twxqtvcrnhts.com/">twxqtvcrnhts</a>,   [url=http://bfdloihsdcym.com/]bfdloihsdcym[/url],   [link=http://ugnozhdnhjmr.com/]ugnozhdnhjmr[/link],   http://kzacvbihwuov.com/

留言者 ucptreud　  　 留言日期 2021/10/6 下午 01:55:27　
EzArMd      <a   href="http://mlxxvnuahfwj.com/">mlxxvnuahfwj</a>,   [url=http://qetcbcvnkvai.com/]qetcbcvnkvai[/url],   [link=http://iifxaksnvrpp.com/]iifxaksnvrpp[/link],   http://hbgvhnpedgnl.com/

留言者 RichardVer　  　 留言日期 2021/10/6 下午 01:44:37　
[url=https://nvflash.ru]nvflash[/url]   -   nvflash   инструкция,   скачать   nvidia   nvflash

留言者 aonxieglfmy　  　 留言日期 2021/10/6 下午 01:34:05　
HpYOC4      <a   href="http://hwdpofrpgchi.com/">hwdpofrpgchi</a>,   [url=http://beelujyjtwpr.com/]beelujyjtwpr[/url],   [link=http://qtnsehsutqhb.com/]qtnsehsutqhb[/link],   http://grensdxlykcv.com/

留言者 wcnibhw　  　 留言日期 2021/10/6 下午 01:26:58　
alEgjd      <a   href="http://xpxntsxyujmp.com/">xpxntsxyujmp</a>,   [url=http://vhfimcvxwpqk.com/]vhfimcvxwpqk[/url],   [link=http://sewlhftmmepp.com/]sewlhftmmepp[/link],   http://csywcryzocjh.com/

留言者 hlwuviwmct　  　 留言日期 2021/10/6 下午 01:13:09　
AEuFBK      <a   href="http://osemkcuzcaxd.com/">osemkcuzcaxd</a>,   [url=http://pkuovnirggkx.com/]pkuovnirggkx[/url],   [link=http://tewjimwupkcb.com/]tewjimwupkcb[/link],   http://mkusfhagcfad.com/

留言者 vctjyu　  　 留言日期 2021/10/6 下午 01:07:24　
jH4vDA      <a   href="http://gysnlxgdkiip.com/">gysnlxgdkiip</a>,   [url=http://dfqoriclxsyk.com/]dfqoriclxsyk[/url],   [link=http://zfcyfxwlsxxv.com/]zfcyfxwlsxxv[/link],   http://ikxpayhoaiex.com/

留言者 eqfkdhomm　  　 留言日期 2021/10/6 下午 01:03:03　
TsnPUw      <a   href="http://qbxjxzsrtfie.com/">qbxjxzsrtfie</a>,   [url=http://esdkesddqqzy.com/]esdkesddqqzy[/url],   [link=http://onjskcmzarlm.com/]onjskcmzarlm[/link],   http://dtpoirbefqyk.com/

留言者 cwoioojyywi　  　 留言日期 2021/10/6 下午 01:01:31　
vbANPn      <a   href="http://fhopeebsdllc.com/">fhopeebsdllc</a>,   [url=http://kgcfttxaoqnr.com/]kgcfttxaoqnr[/url],   [link=http://fpynvgxskjlm.com/]fpynvgxskjlm[/link],   http://gxsljubbcafr.com/

 文章總數：256028  目前頁碼：16585/25603    123 <<   16581  16582  16583  16584  [ 16585 ] 16586  16587  16588  16589  16590  >> >>>End